Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab in Chronic Spontaneous Urticaria
NCT03494881Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Jul 2019
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mepolizumab in chronic spontaneous urticaria (CSU), sponsored by Mayo Clinic. Primary endpoint: Urticaria Activity Score 7 at 10 weeks. Started Jul 2019; status: completed.
02
Drugs
mepolizumab
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT03494881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03494881.